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Abstract
The changes in the regulation of at mitochondrial NADP-isocitrate dehydrogenase (NADP-ICDH) in a rat heart during have been
analysed. Increase of enzyme activity in the cytosol and mitochondria of the heart ischemia was detected. Catalytic properties
of the mitochondrial NADP-ICDH at norm and pathology have been compared on homogeneous enzyme preparations. Enzyme
from the normoxic and ischemic heart showed the same electrophoretical mobility and molecular mass. Enzyme isolated
from the ischemic heart mitochondria demonstrated higher activation energy and lower thermal stability. NADP-isocitrate
dehydrogenase at the normoxic and ischemic conditions exhibited different Km for substrates and regulatory behaviour in
relation to ATP, ADP, 2-oxoglutarate, citrate, malate, reduced and oxidised glutathione. The inhibitory effect of the Fe2+ and
H2O2 mixture associated with the generation of hydroxyl radicals was lower in the ischemic enzyme. We hypothesise that the
specific features of regulation behaviour of NADP-ICDH from the ischemic tissues permits the enzyme to supply NADPH to
the glutathione reductase/glutathione peroxidase system. (Mol Cell Biochem 294: 97–105, 2007)
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Introduction
The role of free radical processes in the aetiology of ischemia
and myocardial infarction is widely accepted [1–4]. It is con-
sidered that the reactive oxygen species (ROS) formed in mi-
tochondrial and microsomal oxidative reactions contribute
to the development of cardiomyocite damage. Mitochondria
are a major cellular source of ROS. The generation of super-
oxide anion depends on the respiration rate and the reduced
state of electron chain carriers support the formation of su-
peroxide ion by one-electron transfer reactions [5, 6]. Ad-
ditionally, defective oxidative phosphorylation [7], degrada-
tion of ATP, xanthine [8, 9] and Fe-binding proteins, and free
Fe2+ accumulation [10–12] increase the generation of ROS in
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mitochondria under the ischemic conditions. The glutathione
reductase/glutathione peroxidase system (GRGP-system) has
been proposed as a main mechanism of ROS-level regulation
[10]. This mechanism plays an important role in H2O2 detox-
ification and might prevent the formation of more aggressive
hydroxyl radical by the Fenton reaction [11]. The activity
of the GRGP-system primarily depends on NADPH levels
needed for the reposition of the reduced glutathione [13].
Reaction catalysed by the NADP-dependent isocitrate de-
hydrogenase (NADP-ICDH) plays a key role in NADPH sup-
ply in rat cardiomyocites [14]. Using a NIH3T3 cell line, Jo
et al. [15] showed that mitochondrial NADP-ICDH acted
as an antioxidative enzyme. The two NADP-ICDH isoen-
zymes in mammalian tissues were shown to differ in their
2006
98
distribution, sub-cellular localisation and some molecular
and catalytic properties [16–19]. Earlier we reported the
properties of the ischemic cytoplasmic NADP-ICDH from
a rat heart and showed that enzyme could serve as an al-
ternative to the pentose phosphate pathway as a source of
NADPH at pathology [20]. It has not been excluded that the
NADPH formed by mitochondrial NADP-ICDH in oxidative
decarboxylation of threo-Ds-isocitrate might be essential for
NADPH supply of the myocardial GRGP-system. Although,
little is known about the functioning of mitochondrial NADP-
ICDH in the myocardium, the high catalytic activity and the
specific mRNA expression indicates its regulation at gene
level under specific conditions [21, 22]. The physiological
role of NADP-ICDH in the heart mitochondria is a contro-
versial subject at the present time. Besides the indications
that mitochondrial NADP-ICDH may function as an antiox-
idant there are some evidences suggesting that this enzyme
operates in reverse direction of the tricarboxylic acid cycle
(TAC). It has been proposed that the reverse flux through
NADP-ICDH is coupled with the transhydrogenase reaction
and may play a significant role in fine regulation of the TAC
activity and in the enhancement of energy production [23].
This study aims to characterise the catalytic properties and
regulation of the mitochondrial NADP-ICDH from rat my-
ocardium at normoxia and ischemia and to elucidate the role




NADP, ADP, ATP and glutathione were obtained from
Reanal, Hungary. D, L-Isocitrate (trisodium salt) and 2-
oxoglutarate were from Sigma Chemical Company, London,
U.K. Tris was supplied by Serva, Germany. CM-Cellulose
was purchased from Whatman, London, U.K. CM-Sephadex,
Sephadex G-25 and G-150 was from Pharmacia, Uppsala,
Sweden. All other chemicals were of the highest analytical
grade available.
Experimental procedures
Healthy male rats of the species, Rattus novergicus albino,
weighting 200–250 g maintained on identical diet were used
in the experiments. Experimental myocardial ischemia was
induced by occlusion of the rats left coronary artery for 45 min
[24]. Control rats have been “sham” operated, by unilateral
thoracotomia.
Cell-free extract was prepared by tissue homogenisation
in 0.05 M Tris-HCl-buffer, pH 7.8 containing 1 mM EDTA,
0.3 M sucrose. Suspension was filtered through four layers of
cheesecloth and centrifuged at 3,500 g for 5 min. The pellet
was discarded and supernatant centrifuged at 15,000 g for 15
min. Final supernatant containing cytoplasm NADP-ICDH
activity was discharged. Pellet with intact mitochondria was
washed and centrifuged twice in a minimal volume of 0.05 M
Tris-HCl buffer, pH 7.8 containing 0.175 M KCl. The pellet
was dissolved in 0.05 M Tris-HCl buffer, pH 7.8 and used in
the purification of mitochondrial NADP-ICDH.
The enzyme reaction was followed spectrophotometrically
by measuring the rate of NADPH formation at 340 nm [16].
The reaction mixture consisted of 0.05 M Tris-HCl buffer,
pH 7.8, 0.20 mM MnCl2, 0.05 mM isocitrate, 0.40 mM
NADP. Enzyme unit corresponds to the amount of enzyme,
catalysing the formation of 1 μmol of NADPH per minute
at 25◦C. The protein content of samples was determined ac-
cording to Lowry et al. [25], with modifications of Yu and
Steek [26].
All purification procedures were carried out at 0 to + 4◦C.
After centrifugation and washing, the mitochondrial suspen-
sion was treated with 20% glycerol and 1 % Triton X-100
(v/v).
Contamination by low weight compounds was avoided by
gel-filtration on a Sephadex G-25 column (1.5 × 20.0 cm)
equilibrated with 0.05 M Tris-HCl buffer, pH 7.8, containing
0.10 mM EDTA and 0.50 mM β-mercaptoethanol (buffer A).
Fractions containing the highest NADP-IDH activity were
joined together and applied to a CM-Cellulose column (0.5 ×
13.0 cm) pre-equilibrated with buffer A. Elution of the en-
zyme during ion-exchange chromatography was performed
with the same buffer containing stepwise or linear concen-
tration gradients of KCl. Fractions possessing NADP-IDH
activity were loaded onto a Sephadex G-150 column (2.0 ×
45.0 cm), previously equilibrated with buffer A. The flow
rate of elution was 35, 30 and 25 ml·h−1 on each step of
purification, respectively. Homogeneity of this enzyme was
monitored by electrophoresis in 7.5% polyacrilamide gel as
described by Davis [27] and gels stained with Coomassie
Blue R-250 [28].
Electrophoretical homogeneous mitochondrial NADP-
IDH purified from control, normoxic (86.1-fold purified) and
ischemia-induced (104.2-fold) myocardium was used to per-
form a comparative study of enzyme catalytic and regulatory
properties. The molecular mass of NADP-IDH was deter-
mined in the presence or absence of isocitrate and Mn2+
ions at non-saturating and saturating concentrations by gel-
filtration on Sephadex G-150 [29]. Kinetic parameters were
determined by modulating the concentrations of isocitrate,
NADP or Mn2+ ions in the presence of a saturating concen-
tration of NADP (0.40 mM), isocitrate (0.05 mM) or MnCl2
(0.20 mM), respectively.
The effect of temperature on the NADP-IDH activity was
determined after 5 min-incubation of the purified enzyme in a
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reaction mixture at a temperature range between 10 and 70◦C.
Stability of NADP-IDH was estimated by temperature incu-
bation of an appropriated amount of purified enzyme (0.07
mg of protein per tube). At 20 min intervals, aliquots were
withdrawn and analysed for enzyme activity. Protein denat-
uration has determined by spectrophotometer measurement
of the magnitude of light diffusion value (τ ) at 490 nm.
The enzyme regulation in the presence of adenine nu-
cleotides, TAC intermediates, glutathione, Fe2+ ions and
H2O2 was carried out. Co-operation between metabolite in-
hibitors, Fe2+ ions and H2O2, was estimated according to
Kurganov [30]. Type and constants of NADP-ICDH inhibi-
tion (Ki ) was determined according with Dixon and Kornish-
Bouden methods [31].
The statistical significance of the experimental data was
determined by analysis of variance followed by Student t-
tests. Differences between values were considered significant
if P < 0.05. The graphs were plotted using data processed
with programs of linear and parabolic approximation.
Results and discussion
In our previous work [20], we have shown that 45 minutes
of ischemia causes an enhancement of free radical processes
and total antioxidative activity estimated by chemilumines-
cence in cytosol and mitochondria of a rat heart. A 1.5-fold
increase of the α-tocopherol contents in ischemic mitochon-
dria was also observed. These changes were accompanied
by 2.5- and 1.8-fold increase of NADP-ICDH activity in is-
chemic mitochondria and cytosol [20, 32]. Nevertheless, the
control of the free radical processes intensity and total an-
tioxidative activity took place in the presented experiments.
NADP-ICDH was isolated from the heart as a whole taking
into consideration that during infarction the myocardium le-
sions were not limited to the zone of ischemia. Several works
have shown changes in the non-ischemic zone, which were
similar to changes at ischemic disease of heart, specifically
in the activation of lipid peroxid oxidation [33].
The mitochondrial NADP-ICDH of ischemic tissue was
purified by ion exchange chromatography on DEAE-
Cellulose, CM-Cellulose, DEAE-Sepharose and CM-
Sephadex using a linear gradient of 0–200 mM KCl. Fractions
with higher enzyme activity were obtained by chromato-
graphic separation in CM-and DEAE-Cellulose. During the
elution from DEAE-cellulose columns the NADP-ICDH ac-
tivity in 155 mM KCl, the fractions were poorly separated
from the aconitate hydratase activity (data not shown). Puri-
fied NADP-ICDH from normoxic and ischemic mitochondria
migrated through the CM-Cellulose columns as a single peak
in the presence of 22 and 27 mM KCl, respectively, while the
specific activity of enzymes from both mitochondria varied
nearly 2.5 times. The enzyme specific activity from the mito-
chondria of normoxic and ischemic heart had 15.5 and 38.0
unit mg−1 protein, respectively. Other purification parame-
ters were 86.1 and 105.6-fold purification or 3.5 and 4.4%
yield, respectively (Table 1). Yield of NADP-ICDH active
fractions during elution on the Sephadex G-150 column co-
incided with a single peak of total protein (data not shown).
The analysis of purified NADP-ICDH preparations of both
tissues revealed a single protein band with the same elec-
trophoresis’ mobility, Rf 0.43 (Fig. 1), which differed from
the mobility of the cytosolic isoenzyme from the normoxic
or ischemic rat heart, with Rf 0.51 [20]. The purified mito-
chondrial enzyme were electrophoretically homogenous and
appeared be free of cytosolic NADP-ICDH contaminations.
The mitochondrial enzyme from the ischemic heart exhib-
ited an increase of 2.5-fold in the specific activity over the
enzyme from normoxic tissue. This result could be related
to the observed initial differences in enzyme activity of mi-
tochondrial fractions from the normoxic and ischemic heart
detected either by differential centrifugation or ion exchange
chromatography. Ischemia-induced increase of NADP-ICDH
activity in the mitochondria of a rat heart was consistent with
earlier observations for NADP-ICDH from the rat brain cy-
tosol fraction [18]. Correlation between ischemic impairment
and rising of NADP-ICDH activity in the cell cytoplasm of
a rabbit spinal cord was also reported [34]. Thus, the en-
hancement in NADP-ICDH activity could occur in differ-
ent mammalian tissues under ischemic conditions. However,
some earlier studies reported the changes in enzyme activ-
ity only under pathological conditions [16, 34]. In previous
work, we compared the cytosolic enzyme features in nor-
moxic and ischemic tissues and related them to the level of
ROS production [20]. Despite of that, the role and features of
rat heart mitochondrial NADP-ICDH functioning at ischemia
is still far from being understood. In order to elucidate the
mechanisms associated with the enzyme activity changes at
ischemia, the molecular and catalytic properties of mitochon-
drial NADP-ICDH from the normoxic and ischemic rat heart
were compared.
Vertebrate’s NADP-IDH consists of two identical subunits,
which are involved in an association-dissociation mechanism
of the enzyme activity regulation [34]. The substrate plays a
relevant role as modulator of the subunits association or disso-
ciation, as described for the NADP-ICDH from pig liver [35].
However, in the present study, the same molecular mass val-
ues have been found in enzyme from normoxic and ischemic
rat heart (77.6 ± 5.0 kDa). These values were the same in the
presence as well as in the absence of substrates and cofac-
tors. Therefore, NADP-IDH association-dissociation mech-
anisms cannot explain the changes in enzyme activity during
ischemia. We suggest that the changes in activity of mito-
chondrial NADP-ICDH under ischemia could be associated
with some structural or conformational modifications of the
enzyme. The increase in substrate affinity associated with the
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Table 1. Purification of NADP-Isocitrate dehydrogenase from the normoxic and ischemic rat myocardium
Specific activity, Total Times
Exp. Total activity Total protein, (units/mg of yield, purified
Purification step conditions (units)a (mg)a protein)a (%) (total)
Crude extract Normoxia 8.86 ± 0.08 48.1 ± 1.68 0.18 ± 0.05 100.00 1.00
Ischemia 17.15 ± 0.30 48.05 ± 1.75 0.36 ± 0.07 100.00 1.00
Mitochondria + X100 Normoxia 1.30 ± 0.05 3.1 ± 0.30 0.42 ± 0.03 14.67 2.33
Triton X100
Ischemia 3.22 ± 0.07 3.05 ± 0.35 1.06 ± 0.04 18.78 2.94
G-25 Normoxia 1.26 ± 0.03 3.00 ± 0.55 0.42 ± 0.04 14.22 2.33
Ischemia 3.10 ± 0.02 3.00 ± 0.40 1.03 ± 0.02 18.08 2.86
CM-cellulose Normoxia 0.67 ± 0.02 0.24 ± 0.04 2.79 ± 0.01 7.56 15.50
Ischemia 1.54 ± 0.06 0.23 ± 0.05 6.70 ± 0.02 8.98 18.61
G-150 Normoxia 0.31 ± 0.04 0.02 ± 0.02 15.5 ± 0.05 3.50 86.11
Ischemia 0.76 ± 0.04 0.02 ± 0.01 38.0 ± 0.05 4.43 105.60
aThe results are expressed as the means + S.D. derived from three experiments.
Fig. 1. Polyacrilamide gel electrophoresis of the NADP-isocitrate dehydro-
genase from normoxic (a) and ischemic (b) rat heart mitochondria. Band 1
shows a set of marker front. Band 2 – NADP-isocitrate dehydrogenase. Pro-
teins were stained with Coomassie Brilliant Blue R250.
changes of Km for isocitrate and Mn
2+ observed in NADP-
ICDH under ischemia supports this supposition. The values
for Km of normoxic and ischemic NADP-ICDH to isocitrate,
NADP and Mn2+ ions are presented in Table 2. Mitochondrial
NADPH-ICDH from ischemic and normoxic heart had differ-
ent temperature optimums, which were 40 and 50◦C, respec-
tively (Fig 2A). The Arrhenius plot for the enzyme incuba-
tion temperature at the intervals between 10 to 40◦C showed
a breakpoint at 30◦C, resulting in activation energy values
of 1820 kcal between 10 and 30◦C and 5936 kcal between
30 and 40◦C for ischemic NADP-ICDH (Fig. 2B). No break-
point in the Arrhenius plot for the normoxic enzyme has been
identified. The activation energy for the enzyme at the tem-
perature interval between 10 and 50◦C has 7756 kcal. Despite
the lower initial activity, the purified normoxic NADP-ICDH
showed higher thermostability, at 60–70◦C, than at ischemic
conditions. Faster enzyme inactivation and the increase of
light diffusion are other parameters confirming these differ-
ences (Fig. 2C, D). These results allow us to conclude that
mitochondrial NADP-ICDH from the normoxic and ischemic
heart were the same enzyme, however, under ischemia the
enzyme showed higher substrate affinity and lower temper-
ature stability. Thus, temperature breakpoint, higher energy
activation, lower temperature optimum and stability can indi-
cate possible enzyme structure and conformational changes
during the ischemia. Some data point out to the structural
modifications of NADP-ICDH under oxidative stress. In par-
ticular, it was reported that mitochondrial NADP-ICDH con-
tains reduced cysteinyl residues that regulate the enzyme ac-
tivity [36, 37]. Their sulfohydryl groups are susceptible to
modification by ROS, nitric oxid, lipid peroxidation prod-
ucts and S-glutathionylation [38–42]. Modification through
glutathionylation of NADP-ICDH from the HEK293 cells
and intact respiring rabbit heart mitochondria treated with
oxidants may lead to a slight disruption of protein structure
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Table 2. Kinetic proprieties of the purified mitochondrial NADP-Isocitrate
dehydrogenase from the normoxic and ischemic rat heart
Parameters Normoxiaa , μM Ischemia
a
, μM
Km isocitrate 45 ± 5 17 ± 6∗
Km NADP 46 ± 5 46 ± 4
Km Mn
2+ ions 420 ± 15 150 ± 10∗
Ki Fe
2+ ions 50 ± 4 (2) 50 ± 3 (2)
Ki H2O2 450 ± 50 (3) 1630 ± 48∗ (3)
Ki (Fe
2+ + H2O2) 15 ± 2 (2) 25 ± 3∗ (2)
Ki glutathione 150 ± 32 (3) no∗
Ki citrate 159 ± 29 (1) 280 ± 41∗(1)
Ki 2-oxoglutarate 80 ± 26 (1) 250 ± 30∗(1)
aThe results are expressed as the means + S.D. derived from three experi-
ments. (∗) Statistical significant values, P < 0.05. In brackets is marked the
type of inhibition: 1 – competitive; 2 – non-competitive; 3 – mixed.
[42]. It was proposed that this mechanism of activity regu-
lation might prevent enzyme from further oxidation by ROS
to its irreversible forms [42]. Moreover, the glutathionylated
NADP-ICDH is more resistant to protease action and diges-
tion, presumably through slight conformational changes of
its molecules. However, it must be pointed out, that the glu-
tathionylation can inhibit the mitochondrial NADP-ICDH,
when the production of oxidants exceeds antioxidant capacity
[42]. According to our data, mobilisation of the antioxidant
system took place in rat heart mitochondria during occlusion
of the left coronary artery for 45 minutes [32]. Therefore,
NADP- ICDH may participate in the cellular defence system
against oxidative damage by supplying NADPH to mitochon-
dria needed for the regeneration of GSH. Increasing enzyme
activity under the referred conditions may support this con-
clusion.
Our study of the influence of metabolites, which organelle
content could be changed under ischemia, on the normoxic
and ischemic enzyme behaviour showed that the concentra-
tions of ATP and ADP can regulate the activity of NADP-
IDH under ischemic conditions. It is known that the ATP
degradation [13] related to breaking synthesis [8], transport
[43] and ATP utilisation [44], and ADP accumulation leads
to the decrease of ATP/ADP ratio, which is considered as
an indicator of radical metabolic changes under ischemia.
A non-reversible ischemic damage and cell necrosis of car-
diomyocites was accompanied by a 50% decrease of initial
ATP concentrations to 3.5 μM [4, 44]. We showed that the
ATP increase from 3.5 to 250 μM caused a slight increase
of enzyme activity in ischemic mitochondria (118 ± 3%, at
7 μM ATP) when an enzyme inhibition was observed at nor-
moxia (Fig. 3A). At the same time, a slight inhibition by ADP
was observed at concentrations ranging from 5.0 to 40.0 μM
for normoxic and from 2.5 to 250 μM for ischemic enzyme
(Fig. 3A). The absence of an ATP inhibition and a stronger
inhibitory effect of ADP at the physiological concentrations
Table 3. Effects of malate, succinate and fumarate on the activities of NADP-
isocitrate dehydrogenase from the normoxic and ischemic rat myocardium
Activity of % from the
Concentration, NADP-ICDH, control valuea
Metabolites mM normoxia Ischemia
Malate 0.1 90 ± 4 60 ± 4∗
0.25 87 ± 4 55 ± 5∗
0.5 85 ± 5 52 ± 4∗
1 83 ± 7 40 ± 6∗
1.5 80 ± 5 35 ± 4∗
Succinate 0.1 85 ± 6 80 ± 4
0.25 80 ± 4 77 ± 6
0.5 74 ± 5 74 ± 6
1 70 ± 4 70 ± 5
1.5 65 ± 4 65 ± 5
Fumarate 0.1 78 ± 4 72 ± 4
0.25 74 ± 4 65 ± 3
0.5 73 ± 5 65 ± 6
1 70 ± 4 63 ± 5
1.5 68 ± 3 60 ± 6
aThe results are expressed as the means ± S.D. derived from 3–5 experi-
ments. (∗) Statistical significant values, P < 0.05.
under ischemia could reflect other metabolic functions of this
enzyme under oxidative stress [4, 12, 45].
We also analysed the influence of some di- and tricar-
boxylic acids, including 2-oxoglutarate, citrate, malate, fu-
marate and succinate, on NADP-ICDH activity from both
tissues. Inhibitory effects of these intermediates on NADP-
ICDH were detected. But the effects of citrate, 2-oxoglutarate
and malate were different for the enzyme from the nor-
moxic and ischemic tissues. The 2-oxoglutarate behaved as
a competitive inhibitor with respect to isocitrate. Ki for 2-
oxoglutarate had values of 80 and 205 μM, for the normoxic
and ischemic enzyme, respectively (Table 2). On the con-
trary, citrate (Table 2) and malate (Table 3) were stronger
inhibitors of NADP-IDH under ischemia than at normoxia,
while the fumarate and succinate had no significant effect
on the enzyme activity (Table 3). These results may indi-
cate that mitochondrial NADP-ICDH under ischemic con-
ditions exhibited an abnormal catalytic behaviour. Interest-
ingly, the strongest NADP-ICDH inhibitor at normoxia, 2-
oxoglutarate, had lower inhibitory effect under ischemia. It
should be taken into account that 2-oxoglutarate serves as
the main nitrogen acceptor and it is a precursor of glutamate
[18, 20]. Hence, under ischemia the changes of enzyme be-
haviour in relation to 2-oxoglutarate can stimulate the amino
acids biosynthesis [46] and utilisation of accumulated the
TAC intermediates [43]. At the same time it could be also
proposed that the increase of the enzyme activity and sub-
strate affinity under ischemia may promote the enhancement
of NADPH supply for the GRGP-system, activity of which
increases during oxidative stress [13, 47].
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Fig. 2. The influence of temperature on NADP-isocitrate dehydrogenase activity from normoxic (1) and ischemic (2) rat heart mitochondria. A. Determination
of the enzyme temperature optimum. Data are means ± S.D. (n = 4) B. Arrhenius plot of the data from 10◦C to 50◦C and 10◦C to 40◦C. Data are means ± S.D.
(n = 4). C. Determination of the enzyme thermo-inactivation. Data are means ± S.D. (n = 4). D. Determination of the enzyme thermostability. Determination of
the enzyme thermostability was estimated spectrophotometrically by measuring the magnitudes of light diffusion value (τ ) of NADP-isocitrate dehydrogenase
preparations at 490 nm. The results are expressed as the means + S.D. (n = 4).
Fig. 3. The influence of ATP (A) and ADP (B) on NADP-isocitrate dehydrogenase activity from normoxic (1) and ischemic (2) rat heart mitochondria. The
results are expressed as the means + S.D. derived from three experiments.
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Fig. 4. The influence of Fe2+ and H2O2 mixture (A) and glutathione (B) on NADP-isocitrate dehydrogenase activity from normoxic (1) and ischemic (2)
rat heart mitochondria. Determination of the type of Fe2+ and H2O2 co-operation during inhibition of NADP-isocitrate dehydrogenase from mitochondria of
normoxic (I) and ischemic (II) rat heart was performed according to Kurganov. The enzyme activity assayed as a function of NADPH concentrations using 0.4
mM NADP, 0.2 mM MnCl2 and 0.05 mM isocitrate in the presence of 0.10 mM H2O2. The 0.02–0.16 mM concentration range of Fe
2+ ions were used. 1 –
V1,2/V0 – ratio of the enzyme reaction velocity in the presence or absence of two inhibitors; V1/V0 × V2/V0 – product of ratio of the enzyme reaction velocity
at the presence of the first inhibitor (Fe2+ ions) and the second inhibitor (H2O2) to initial velocity. Data are means ± S.D. (n = 5).
The influence of substrates of the Fenton reaction on the
NADP-ICDH activity was evaluated. Strong inhibition of
NADP-ICDH by H2O2 in mitochondria of healthy rats was
observed (Table 2). At the same time, the inhibitory effect of
Fe2+ was not different at both normoxic and ischemic con-
ditions. However, when combined, Fe2+ and H2O2 exhibited
pronounced inhibitory effect at normoxia (lower Ki values)
when compared with ischemia (higher Ki values) (Table 2).
The analysis of interactions between these two inhibitors al-
low us to conclude that the NADP-ICDH inhibition by Fe2+
and H2O2 was characterised by a synergistic effect expressed
in a lower extent under ischemic conditions (Fig. 4A). Fe2+
and H2O2 interactions lead to the formation of hydroxyl rad-
ical, an aggressive ROS species. Therefore, decrease of the
NADP-ICDH activity can be associated with the enzyme ox-
idation through the carbonylation. This suggestion is consis-
tent with the fact that protein carbonylation was a common
biomarker of severe oxidative damage in proteins [48]. It
cannot be excluded that regulation of the enzyme by Fe2+
and H2O2 might be connected with its participation in the
NADPH generation for the GRGP-system. Under ischemia,
the lowest enzyme repression in the presence of the compo-
nents of the Fenton reaction can also increase NADPH level
and activate the GRGP-system.
Under our experimental conditions the reduced glutathione
inhibited NADP-ICDH from the normoxic heart mitochon-
dria at the concentrations ranging from 5 to 100 μM, while
had no inhibitory effect on the enzyme from ischemic mito-
chondria (Fig. 4B, Table 2). On the contrary, oxidised glu-
tathione activated the NADP-IDH from the ischemic mito-
chondria at the concentrations ranging from 25 to 125 μM,
whereas it had weaker effect on the enzyme from the nor-
moxic tissue (Fig. 4B). NADP-ICDH activity increased in
10 ± 2% and 53 ± 2% in the presence of 10 μM oxidised
glutathione at normoxia and ischemia, respectively. These
data suggest that the reduced and oxidised glutathione have
different regulatory effects on the activity of the mitochon-
drial NADP-IDH at the normoxic and ischemic conditions.
The observed regulatory effects could be important in the mi-
tochondrial NADP-ICDH and the GRGP-system interaction
in a rat heart under increasing ROS production.
NADP-ICDH activation coupled with the increasing
NADPH production due to particular kinetic and regulatory
enzyme changes can lead to the growth of reduced/oxidized
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glutathione ratio, which in turn is determined by the GP ac-
tivation. This supposition remains in contradiction with the
reverse metabolic flux through NADP-ICDH and its hypoth-
esized role in the fine regulation of the TCA activity [23]. On
the other hand, it is consistent with the suggestion of Jo et al.
[15] based on evidence of antioxidant role of the enzyme ob-
tained from N1H3T3 cells. It must be taken into account that
in heart the mitochondrial NADPH/NADP ratio is more than
50 [49, 50], when in the N1H3T3 cells was less than 1 [23].
Nevertheless, under conditions of severe oxidative stress cre-
ated in myocardium, during ischemia the main consequences
of the TAC repression would be the decrease of NADH level
and suppression of the electron transport. NADH availability
can limit the activity of transhydrogenase to the enhance-
ment of NADPH generation [23, 51]. Some other evidences
related to the antioxidant role of the mitochondrial NADP-
ICDH were also reported [39, 52, 53].
It cannot be excluded that changes in the NADP-ICDH be-
haviour under ischemia might have a regulatory significance
for the functioning of the myocardial antioxidative GRGP-
system. Higher catalytic activity, Km, and differential sensi-
tivity of NADP-ICDH to several metabolites can be explained
on the grounds of adaptation strategies to the oxidative stress
and tissue recovery.
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